SCRS Resource Guide Network

Sites, Sponsors, CROs: Discover the solutions your clinical research teams need with SCRS.


We are uniting science, technology and talent to get ahead of disease together.


GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology,

GSK press releasesGSK press releases 
  • European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention September 19, 2023 10:59am

    Cabotegravir demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV in clinical trials.
    View this post

  • Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia September 15, 2023 4:48pm

    Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
    View this post

  • GSK and Save the Children renew award-winning partnership, with focus on ‘zero dose’ children who have never received a vaccine September 14, 2023 4:00am

    GSK and Save the Children renew their 10-year partnership for a further five years.
    View this post

  • GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator September 11, 2023 3:00am

    Submission included data from trials addressing clinical manifestations of myelofibrosis - splenomegaly, constitutional symptoms and anaemia
    View this post

  • GSK’s regulatory submission accepted for review by Japanese regulator for use of Nucala (mepolizumab) in adults with chronic rhinosinusitis with nasal polyps September 1, 2023 2:55am

    If approved, Nucala would be first anti-interleukin-5 biologic available in Japan for treatment of adults with CRSwNP
    View this post

  • New Shingrix data demonstrate 100% vaccine efficacy in the prevention of shingles in adults aged 50 and over in China August 23, 2023 2:34am

    No cases of shingles (herpes zoster) reported among the participants who received Shingrix in the randomised clinical trial
    View this post

Web Site: www.gsk.com 


  • GlaxoSmithKline
    Pharmaceutical Manufacturing
    980 Great West Road
    United States
    Map It »
  • Videos4
  • News6
  • Last UpdatedJuly 24, 2023 12:39pm EDT